Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.

Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, Bellet M, Cortés J, Elliott R, Pancholi S, Baselga J, Dowsett M, Martin LA, Turner NC, Serra V.

Cancer Res. 2016 Apr 15;76(8):2301-13. doi: 10.1158/0008-5472.CAN-15-0728. Epub 2016 Mar 28. Erratum in: Cancer Res. 2016 Oct 1;76(19):5907.

2.

Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.

Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL.

Cancer Res. 2017 May 1;77(9):2488-2499. doi: 10.1158/0008-5472.CAN-16-2653. Epub 2017 Mar 1.

3.

Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.

Bisi JE, Sorrentino JA, Jordan JL, Darr DD, Roberts PJ, Tavares FX, Strum JC.

Oncotarget. 2017 Jun 27;8(26):42343-42358. doi: 10.18632/oncotarget.16216.

4.

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.

Yang C, Li Z, Bhatt T, Dickler M, Giri D, Scaltriti M, Baselga J, Rosen N, Chandarlapaty S.

Oncogene. 2017 Apr 20;36(16):2255-2264. doi: 10.1038/onc.2016.379. Epub 2016 Oct 17.

5.

Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.

Knudsen ES, Witkiewicz AK.

Oncotarget. 2016 Oct 25;7(43):69111-69123. doi: 10.18632/oncotarget.11588.

6.

Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity.

Lamb R, Lehn S, Rogerson L, Clarke RB, Landberg G.

Cell Cycle. 2013 Aug 1;12(15):2384-94. doi: 10.4161/cc.25403. Epub 2013 Jun 26.

7.

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.

Ladd B, Mazzola AM, Bihani T, Lai Z, Bradford J, Collins M, Barry E, Goeppert AU, Weir HM, Hearne K, Renshaw JG, Mohseni M, Hurt E, Jalla S, Bao H, Hollingsworth R, Reimer C, Zinda M, Fawell S, D'Cruz CM.

Oncotarget. 2016 Aug 23;7(34):54120-54136. doi: 10.18632/oncotarget.10852.

8.

Treating cancer with selective CDK4/6 inhibitors.

O'Leary B, Finn RS, Turner NC.

Nat Rev Clin Oncol. 2016 Jul;13(7):417-30. doi: 10.1038/nrclinonc.2016.26. Epub 2016 Mar 31. Review.

PMID:
27030077
9.

Clinical development of CDK4/6 inhibitor for breast cancer.

Iwata H.

Breast Cancer. 2018 Jul;25(4):402-406. doi: 10.1007/s12282-017-0827-3. Epub 2018 Feb 1. Review.

PMID:
29392622
10.

Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.

Asghar US, Barr AR, Cutts R, Beaney M, Babina I, Sampath D, Giltnane J, Lacap JA, Crocker L, Young A, Pearson A, Herrera-Abreu MT, Bakal C, Turner NC.

Clin Cancer Res. 2017 Sep 15;23(18):5561-5572. doi: 10.1158/1078-0432.CCR-17-0369. Epub 2017 Jun 12.

11.

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.

Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES.

Oncogene. 2010 Jul 15;29(28):4018-32. doi: 10.1038/onc.2010.154. Epub 2010 May 17.

PMID:
20473330
12.

Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.

Kwapisz D.

Breast Cancer. 2018 Sep;25(5):506-516. doi: 10.1007/s12282-018-0864-6. Epub 2018 Apr 26. Review.

PMID:
29700711
13.

Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.

Kwapisz D.

Breast Cancer Res Treat. 2017 Nov;166(1):41-54. doi: 10.1007/s10549-017-4385-3. Epub 2017 Jul 24. Review.

PMID:
28741274
14.

Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE, Zamboni WC, Wong KK, Perou CM, Sharpless NE.

J Natl Cancer Inst. 2012 Mar 21;104(6):476-87. doi: 10.1093/jnci/djs002. Epub 2012 Feb 1.

15.
16.

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.

Wardell SE, Ellis MJ, Alley HM, Eisele K, VanArsdale T, Dann SG, Arndt KT, Primeau T, Griffin E, Shao J, Crowder R, Lai JP, Norris JD, McDonnell DP, Li S.

Clin Cancer Res. 2015 Nov 15;21(22):5121-5130. doi: 10.1158/1078-0432.CCR-15-0360. Epub 2015 May 19.

17.

Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.

Owsley J, Jimeno A, Diamond JR.

Drugs Today (Barc). 2016 Feb;52(2):119-29. doi: 10.1358/dot.2016.52.2.2440528. Review.

PMID:
27092341
18.

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ.

Breast Cancer Res. 2009;11(5):R77. doi: 10.1186/bcr2419.

19.

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.

Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F, Wu JY, Toniatti C, Heffernan TP, Powis G, Kwong LN, Kopetz S.

Oncotarget. 2016 Jun 28;7(26):39595-39608. doi: 10.18632/oncotarget.9153.

20.

Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer.

Harada M, Morikawa M, Ozawa T, Kobayashi M, Tamura Y, Takahashi K, Tanabe M, Tada K, Seto Y, Miyazono K, Koinuma D.

Cancer Sci. 2019 Jan;110(1):209-220. doi: 10.1111/cas.13841. Epub 2018 Nov 16.

Supplemental Content

Support Center